Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A
Funding & venture capital News
The investment stands to support Syremis' advancing pipeline and its lead program, a dual M1/M4 muscarinic agonist dubbed ST-905 that's currently in ...
